Ray, P., Okal, A., Perales, M., Raj, S., Shouval, R., Papp, E., Ansari, S., Juluri, K. R., Przespolewski, A., Roy, D., Thompson, E., Rytlewski, J. A., Bleickardt, E., Crotta, A., Campbell, T. B., Peiser, L. (2025). Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study. Blood. https://doi.org/10.1182/blood-2025-3549